secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2026-08-21T20:31:12+00:00
Accession:  0001104659-26-099712
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma establishes new $200M ATM offering program with Jefferies
-------------------------------------------------------------------------

- Entered Open Market Sale Agreement with Jefferies LLC on Aug 21, 2026, for up to $200M in common stock.
- Sales made via new Form S-3 shelf registration filed Aug 21, 2026; Jefferies fee up to 3.0% of gross proceeds.
- Prior ATM program terminated July 20, 2026; no further sales under the Feb 13, 2026 prospectus supplement.
- No minimum sales required; proceeds used for general corporate purposes, if any shares are sold.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465926099712/0001104659-26-099712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465926099712/tm2623689d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-099712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer